These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34023935)

  • 21. Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses
    Vishwakarma P; Yadav N; Rizvi ZA; Khan NA; Chiranjivi AK; Mani S; Bansal M; Dwivedi P; Shrivastava T; Kumar R; Awasthi A; Ahmed S; Samal S
    Front Immunol; 2021; 12():613045. PubMed ID: 33841395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of the SARS-CoV-2 S-Protein Glycosylation in the Interaction of SARS-CoV-2/ACE2 and Immunological Responses.
    Ramírez Hernández E; Hernández-Zimbrón LF; Martínez Zúñiga N; Leal-García JJ; Ignacio Hernández V; Ucharima-Corona LE; Pérez Campos E; Zenteno E
    Viral Immunol; 2021 Apr; 34(3):165-173. PubMed ID: 33605822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
    Rowland R; Brandariz-Nuñez A
    Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.
    Mehdipour AR; Hummer G
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33903171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
    Kim CH
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycosylation of SARS-CoV-2: structural and functional insights.
    Shajahan A; Pepi LE; Rouhani DS; Heiss C; Azadi P
    Anal Bioanal Chem; 2021 Dec; 413(29):7179-7193. PubMed ID: 34235568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry.
    Mannar D; Leopold K; Subramaniam S
    Sci Rep; 2021 Jun; 11(1):12448. PubMed ID: 34127709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the Potential of Chemical Inhibitors for Targeting Post-translational Glycosylation of Coronavirus (SARS-CoV-2).
    Tripathi N; Goel B; Bhardwaj N; Vishwakarma RA; Jain SK
    ACS Omega; 2022 Aug; 7(31):27038-27051. PubMed ID: 35937682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex.
    Bhattacharya M; Sharma AR; Mallick B; Sharma G; Lee SS; Chakraborty C
    Infect Genet Evol; 2020 Nov; 85():104587. PubMed ID: 33039603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
    van de Leemput J; Han Z
    Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V.
    Bollavaram K; Leeman TH; Lee MW; Kulkarni A; Upshaw SG; Yang J; Song H; Platt MO
    Protein Sci; 2021 Jun; 30(6):1131-1143. PubMed ID: 33786919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.
    Bhatt AN; Kumar A; Rai Y; Kumari N; Vedagiri D; Harshan KH; Chinnadurai V; Chandna S
    Life Sci; 2022 Apr; 295():120411. PubMed ID: 35181310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.
    Madan T; Biswas B; Varghese PM; Subedi R; Pandit H; Idicula-Thomas S; Kundu I; Rooge S; Agarwal R; Tripathi DM; Kaur S; Gupta E; Gupta SK; Kishore U
    Am J Respir Cell Mol Biol; 2021 Jul; 65(1):41-53. PubMed ID: 33784482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules.
    Stravalaci M; Pagani I; Paraboschi EM; Pedotti M; Doni A; Scavello F; Mapelli SN; Sironi M; Perucchini C; Varani L; Matkovic M; Cavalli A; Cesana D; Gallina P; Pedemonte N; Capurro V; Clementi N; Mancini N; Invernizzi P; Bayarri-Olmos R; Garred P; Rappuoli R; Duga S; Bottazzi B; Uguccioni M; Asselta R; Vicenzi E; Mantovani A; Garlanda C
    Nat Immunol; 2022 Feb; 23(2):275-286. PubMed ID: 35102342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.